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Cardiac function, cell death and cell proliferation.  
Heart diseases represent the most frequent cause of death in the western world 
and ventricular fibrillation is the main cause of sudden death in patients who have had a 
heart attack, killing about 15% of patients within three years of their attack 
(Gheorghiade M et al 1998; Kjekshus J 1990). Many heart diseases result from myocyte 
loss in the absence of appropriate myocardial repair which leads to progressive heart 
failure and cardiovascular insufficiency. During the last decade many investigators 
attempted to modify the ratio “cardiac tissue damage/repair” by means of stem cell 
based regenerative therapies (Marbán E et al 2010).  
General properties of stem cells.  
Stem cells can be classified by their ability to divide and to produce 
differentiated cells (Fig. 1). Totipotent cells have a total differentiation capacity. They 
can divide and produce all the different types of cells in an organism. Totipotent cells 
can specialize into pluripotent cells that can give rise to most of the tissues necessary for 
fetal development. The pluripotent cells have the potential to differentiate into 
multipotent cells. Stem cells can also be classified into adult stem cells (ASC) and 
embryonic stem cells. A typical ASC is one which, on division, results in one daughter 
cell that can further differentiate and replenish a whole compartment, while the other 
cell remains fully self-renewing. The ultimate fate of progeny is the generation of a 
functionally competent mature cell (Fuchs E et al 2000). This model of cell growth has 
been clearly established in the hematopoietic system. However, it is commonly applied 
to all self-renewing organs. 
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Stem cells and the heart.  
In the past few years the ability of stem cells to regenerate tissues has been 
clearly documented. Specifically, experimental observations have shown the plasticity 
of stem cells indicating that in appropriate conditions stem cells can repair a damaged 
tissue independently from their origin (Lagasse E et al. 2000; Jakson KA et al. 1999; 
Fallon J et al. 2000; Orlic D et al. 2001a; Orlic D et al. 2001b; Kocher AA et al. 2001; 
Condorelli G et al. 2001). In this respect adult stem cells obtained from bone marrow 
may turn into heart and brain or, viceversa, brain and muscle derived stem cells may 
generate bone marrow (Reynolds BA e al. 1992; Johansson CB et al. 1999a; Johansson 
CB et al. 1999b; Clarke DL et al. 2000; Kondo T et al. 2000; Horner PJ et al. 2000; 
Arvidsson A et al. 2002; Monje ML et al. 2002; Beltrami AP et al. 2003; Oh H et al. 
2003). 
Recently, a major paradigm shift has taken hold of the cardiovascular 
community fuelled by the discovery that stem cells have the capacity to differentiate 
into the three major cell types of the myocardium: smooth muscle, endothelial, and 
cardiomyocyte (Quaini F et al. 2002; Beltrami AP et al. 2003; Urbanek K et al. 2003). 
The persistence of this observation through independent validation in multiple 
laboratories throughout the world bodes well for the potential of this area to have a 
major impact upon cardiovascular research (Boheler KR et al. 2002; Hierlihy AM et al. 
2002; Oh H et al. 2003). Despite several disputes regarding frequency, the prevailing 
opinion is that such transdifferentiation events do occur (Anversa P et al. 2002; Balsam 
LB et al. 2004; Murry CE et al. 2004; Chien KR 2004; Anversa P et al. 2004). In the 
past few years, coincident efforts by several groups have demonstrated integration of 
stem cells into the intact heart (Malouf NN et al. 2001; Jackson KA et al. 2001; Orlic D 
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et al. 2001a; Behfar A et al. 2002). Some studies have observed repopulation of 
damaged myocardium by bone marrow-derived stem cells that confer improved 
hemodynamic function  (Orlic D et al. 2001a; Orlic D et al. 2001c). Thus the question 
no longer appears to be whether cardiomyocyte replacement occurs, but rather what are 
the characteristics of the progenitor population, how efficiently can such cells integrate 
into the functioning myocardium, and whether the process can be manipulated by 
genetic or biochemical techniques to potentiate the regenerative properties of these 
cells. 
Controversies and feasibility of cardiac stem cell therapy.  
Sorting out the specifics of much of the current debate in cardiac stem cell 
research is clouded by multiple controversies. First, estimates vary widely with regard 
to the capacity of donated cells to survive and subsequently integrate into host tissue. 
Second, skeptics raised concerns over fusion between donated cells and the adopted 
home tissue creating a chimeric DNA that could masquerade as integration. Third, there 
is an issue of whether donated stem cells promote recruitment of endogenous 
progenitors to assist in regeneration. Fourth, the influence of endogenous factors such as 
cytokines, growth factors, and the local cellular milieu upon stem cells remains poorly 
understood (Terada N et al. 2002; Ying QL et al. 2002; Vassilopoulus G et al. 2003; 
Wang X et al. 2003; Spees JL et al. 2003; Nygren JM et al. 2004; Alvarez Dolado M et 
al. 2003; Oh H et al. 2003; Shi D et al. 2004). Resolution of these key issues will 
ultimately determine the efficacy and feasibility of stem cell therapy as an interventional 
approach to repair damaged or failing myocardium. 
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Electrical and mechanical competence of the newly formed myocardial tissue.  
Most stem cell treatments have been found to result in different degrees of 
amelioration of the mechanical performance of the heart. However, in order for cell 
therapy to be widely clinically applicable, the optimal cell has to be compatible both 
mechanically and electrically with the host myocardium. Establishing appropriate 
electrical connections among newly formed myocytes and surrounding, spared 
myocytes is of paramount importance for a stable recovery of normal cardiac function. 
So far, information on this issue is fragmented and no comprehensive study exists 
aimed at establishing whether the mechanical improvement of cardiac function in 
patients undergoing stem cell therapy for a given heart condition is associated with an 
increase, decrease or no changes in the risk of arrhythmias (Zhang YM et al. 2002; 
Chang MG et al. 2006; Kuhlmann MT et al. 2006; Mills WR et al. 2007). Pro-
arrhythmia after cell therapy have been attributed to several reasons including: l) 
heterogeneity of action potentials between the native and the transplanted stem cells; 2) 
intrinsic arrhythmic potential of injected cells; 3) increased nerve sprouting induced by 
stem cell injection; and 4) local injury or edema induced by intramyocardial injection 
(Makkar RR et al. 2003). The nature of the injected cell may have the most impact on 
arrhythmogenesis after transplantation. For instance myoblasts (precursor of skeletal 
myocytes) and stem cells of different origin differ in their inherent electrophysiologic 
properties and in their ability to couple electromechanically both among themselves and 
with host cardiomyocytes. Limited clinical data available thus far suggest that 
arrhythmias are more likely to occur after myoblast than after stem cell transplantation 
(Smits PC et al. 2003; Menasche et al. 2001; Menasche et al. 2003). Often, the 
occurrence of arrhythmias is negatively correlated with the ability of the newly formed 
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tissue to adopt a cardiac fate or to couple electrically with the spared myocardium 
(Hahn JY et al. 2008; Roell W et al. 2007). Finally, limited clinical experience suggests 
that proarrhythmic effects of cell therapy may be transient (Makkar RR et al. 2003; 
Strauer BE et al. 2001; Assmus B et al. 2002; Stamm C et al. 2003; Perin EC et al. 
2003; Tse HF et al. 2003). Nonetheless, because the occurrence of cardiac arrhythmia is 
highly unpredictable, long-term follow-up studies of cell transplant recipients would 
seem to be essential for understanding the natural course of stem cell induced 
arrhythmogenesis, if any.  
Cardiac electrical instability in myocardial infarction.  
Although the proneness to arrhythmias is increased in both the acute and chronic 
phase of myocardial infarction the mechanisms of the increased electrical instability are 
different. 
Acute Ischemia. The most important electrical changes that occur upon acute 
and complete block of coronary circulation include a fall in diastolic membrane 
potential and initial lengthening, followed by shortening, of the action potential 
duration, associated with a fall in amplitude and maximal rate of depolarization (Wit AL 
et al. 1993). Additionally, the effective refractory period is prolonged relative to action 
potential duration and conduction velocity is markedly decreased. Finally excitability, 
which is initially increased, is subsequently decreased and eventually results in 
inexcitability. Arrhythmias are a serious complication of acute ischemia. Most 
experimental studies indicate that a first burst of tachycardia is seen between two and 10 
minutes from coronary ligature. Yet evolution into ventricular fibrillation is rare during 
this phase generally termed phase Ia. This pattern is followed by a 10 minute period of 
relative quiescence. A second phase (phase Ib) of arrhythmias appears between 20 and 
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30 minutes from occlusion. The percentage of animals showing these arrhythmias is less 
than in phase Ia but the evolution towards ventricular fibrillation and death is more 
frequent (Smith WTt et al. 1995). 
Chronic Infarct. Ventricular myocytes surviving an acute period of ischemia 
undergo a number of adaptations that reflect in specific electrophysiological features. 
Crucial changes also occur in the extracellular matrix. Adaptation is not restricted to the 
infarcted zone but involves peri-infarct myocytes and cells remote from the infarct zone. 
When the infarct is in the left ventricle, important alterations also occur in the right 
ventricle presumably because of a neurohumoral activation which produces modulating 
factors that appears in the circulation and influences the whole heart. Arrhythmias are a 
frequent complication of healing (hours to 2 weeks) and healed (weeks to months) 
infarct. During the healing process following an infarct electrophysiological 
modifications occur in both subepicardial myocytes and subendocardial Purkinje fibres 
adjacent to the infarct border (Boyden Pa et al. 1995; Pinto JM et al. 1999). In addition 
conduction velocity is slowed down in subepicardial cells overlaying the necrotic area 
and critical defects are found in cell connections and gap junctions. Published data 
indicate that at 3-5 days post-infarct inducibility of tachycardias is closely related to the 
disorganisation of the gap junctions extending through the entire thickness of the 
subepicardial layers. In healed myocardial infarction (2 weeks and several months) 
adapative processes are not limited to cells in the infarct zone and to cells close to the 
scar. Electrical abnormalities  also occur in cells remote to the scar and these changes 
are different from the alterations in the adjacent cells. Infarct and peri-infarct cells are 
characterized by marked regional differences involving action potential duration, 
excitability, and refractoriness and its dispersion. Also, irregularities in gap junctions 
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which started already during the healing phase become more pronounced. 
Concomitantly with reduction in gap junction coupling between the cells other 
fundamental alterations occur in the extracellular spaces with development of 
microfibrosis between the cells. Propagation is impaired and may follow a zig-zag 
pattern, especially when an extra-systole is generated (Peters NS et al. 1997). The 
reported changes in gap junction, in their regional distribution and the development of 
extracellular fibrosis have important consequences for the inducibility and persistence 
of arrhythmias. Finally, cells at a distance from the scar are characterized by a marked 
hypertrophy, as shown by morphometric and membrane capacitance indexes, thus 
increasing  electrical instability  
Resident cardiac progenitor cells (CPCs) for heart repair.  
The heart contains several cohorts of resident cardiac progenitor cells (CPCs) 
which have been characterized by different groups (Beltrami AP et al. 2003; Oh H et al. 
2003, Martin CM et al. 2004, Messina E et al. 2004, Laugwitz KL et al. 2005, Limana F 
et al. 2007, Davis DR et al. 2010) and are considered to be responsible for tissue 
homeostasis (Quaini F et al. 2002). Because CPCs are intrinsically programmed to 
generate myocardium, they appear best suited for the complex task of reconstituting 
tissue that is lost with a myocardial infarction (Chamuleau SA et al. 2009) and restoring 
the blood supply in the damaged area (Dawn B et al. 2005). These properties of CPCs 
would be expected to improve the organization and functional integration of newly 
formed tissues with the spared tissue, minimizing heterogeneous electrical remodeling 
and poor intercellular coupling occurring with numerous cardiac regenerative treatments 
(Hahn JY et al 2008; Wang D et al. 2010). Thus, mending of the heart promoted by 
CPCs can be an appropriate substrate to explore the proarrhythmic or antiarrhythmic 
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consequences of stem cell based myocardial regeneration. CPCs have been reported to 
express c-Met and insulin-like growth factor-1 (IGF-1) receptors and synthesize and 
secrete the corresponding ligands, hepatocyte growth factor (HGF) (which mobilizes 
CPCs) and IGF-1 (which promotes their survival and proliferation) (Urbanek K et al. 
2005). In infarcted hearts of dogs (Linke A et al. 2005), mice (Urbanek K et al. 2005) 
and rats (Rota M et al 2008), the intramyocardial injection of HGF and  IGF-1 enhanced 
the translocation of CPCs from the surrounding myocardium to the dead tissue and their 
viability and growth within the damaged area, fostering cardiac regeneration and 
improving mechanical function. Accordingly, one would expect that activating the 
lineage commitment and progeny formation of resident CPCs, via the HGF/IGF-1-
receptor systems, can also ameliorate the electrical competence of chronic myocardial 
infarction. Importantly, post-MI ventricular remodeling contributes to end stage heart 
failure (Gheorghiade M et al. 1998), and lethal arrhythmias are responsible for up to 
half the deaths in heart failure (Kjekshus J 1990). 
Recently, it has been shown that High-Mobility Group Box-1 (HMGB1) protein, 
a mediator of the inflammatory response, when administered to CPCs, both in vitro and 
in vivo, modulates their function. Additionally, despite its primary inflammatory role, 
HMGB1-dependent signaling has protective effects in acute myocardial ischemia. In 
fact, it has been found that HMGB1 blockade leads to exaggerated scarring and more 
severe ventricular dilation in acute MI (Kohno et al. 2009). Injection of HMGB1 in a 
mouse model of myocardial infarction was found to promote c-kit+ cell proliferation 
and enhanced myocardial regeneration (Limana et al. 2005). Direct and indirect effects 
have been proposed to account for the HMGB1-induced CPC proliferation. In fact c-
kit+ cells express RAGE (Limana et al. 2005) and respond to HMGB1; further, cardiac 
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stromal cells exposed to HMGB1 secrete a variety of pro-inflammatory and pro-
angiogenic cytokines that also modulate CPC function (Rossini et al. 2008). Taken 
together, these results suggest that inflammatory modulation and pro-repair signaling by 
HMGB1 converge into an integrated pathway causing CPC activation at early stages 
after ischemia, followed by attenuation of the inflammatory machinery and prevention 
of ventricular remodeling at later stages. So far no data have been obtained on the 
electrophysiological consequences of cardiac repair mediated by CPCs activation via 
HMGB1 intramyocardial delivery. Although the efficacy of HMGB1 in acute ischemia 
has not been fully elucidated we believe that this analysis would provide important data 
in order to evaluate the electrical competence of the regenerated heart in the early stages 
of myocardial injury. 
 
Aim of the study. By following an approach from the intact animal to tissue, cellular, 
and molecular levels we tested the hypothesis that mobilization of CPCs: (i) either 
through locally delivered Hepatocyte Growth Factor and Insulin-Like Growth Factor-1 
to repair chronic myocardial infarction (Protocol A, see Table 1), (ii) or through 
intramyocardial administration of HMGB1 to restore cardiac function in acute ischemia 
(Protocol B, see Table 2), lowers the proneness to arrhythmias.  
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Fig. 1. Differentiation potential of stem cell lineages. 
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Protocol A: Mobilization of CPCs by GF injection  
                     (HGF + IGF1), in chronic myocardial infarction. 
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A1. Animals and housing. 
All experimental procedures were approved by the Veterinarian Animal care and 
use Committee of Parma University and conformed with the National Ethical 
Guidelines (Italian Ministry of Health; D.L.vo 116, January 27, 1992) and the Guide for 
the Care and Use of Laboratory Animals (NIH publication no. 85–23, revised 1996). 
The study population consisted of 133 rats male Wistar rats (Rattus norvegicus) 
bred in our departmental animal facility, aged 12-14 wk, weighing 300-350 g. The 
animals were kept in single-sex groups of four individuals from weaning (4wk after 
birth) until the onset of the experiments, in a temperature-controlled room at 20–24°C, 
with the light on between 7.00 AM and 7.00 PM. The bedding of the cages consisted of 
wood shavings, and food and water were freely available. 
The animals were subjected either to myocardial infarction (MI group) or sham 
operation (SO group). Four weeks later, all animals were treated with growth factors 
(GFs) or vehicle (V) and assigned to the following groups: MI+GF, MI+V and SO+V. 
GFs were Hepatocyte Growth Factor (HGF) and Insulin-Like Growth Factor-1 (IGF-1). 
Owing to the multifactorial nature of arrhythmogenesis in myocardial infarction, 
all animals with anatomically documented MI were used in the study, even if infarct 
size was small.  
 
A2. General outlines of the experimental protocol A.  
The experimental design and measurements performed in the study are 
summarized in Table 1. 
Sixty rats were chronically instrumented with a Telemetry-ECG system (TE rats, 
Table 1). After one week, a 30-minute continuous baseline ECG was recorded to rule 
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out the presence of spontaneous arrhythmias. The animals were then subjected either to 
myocardial infarction (MI group, 45 rats) or to sham operation (SO group, 15 rats) and, 
four weeks later, investigated for vulnerability to arrhythmias and cardiac mechanical 
performance by (i) telemetry-ECG recording in baseline condition and stress-induced 
autonomic stimulation (social stress procedure) and (ii) echocardiograpy. Afterwards, 
all rats were re-operated on and intra-myocardial injections of growth factors or vehicle 
were performed (MI+GF group, 22 rats; MI+V, 23 rats; SO+V, 15 rats). Simultaneously 
with GF or V (GF/V) administration, selected subgroups of MI+GF (n=14) and MI+V 
rats (n=11) were also treated with 5-Bromo-2’-deoxycytidine (BrdC), to evaluate the 
cumulative amount of cell proliferation. Two weeks later, vulnerability to arrhythmias 
and cardiac mechanical function were re-determined by a new series of telemetry-ECG 
and echocardiographic measurements and, subsequently, hemodynamic data were 
invasively collected. Finally, at sacrifice, the heart was perfusion fixed for anatomical 
studies (all TE rats), and morphometric and immunohistochemical studies (selected 
subgroups of animals). 
In 43 additional rats, assigned to the MI+GF (n=24) or MI+V (n=19) groups, 
further electrophysiological investigations were performed by Epicardial Multiple-lead 
recording (EM rats, Table 1). In all animals, four weeks after MI, 25-64 unipolar 
electrograms (EGs) were collected from as many sites of the infarcted epicardial surface 
and surrounding areas. EGs were recorded during sinus rhythm or specific pacing 
protocols for determining basic cardiac electrophysiological properties (conduction 
velocity, excitability and refractoriness) as well as dispersion of refractoriness and QT 
interval duration. Subsequently, growth factors or vehicle were administered to the 
proper subgroups. Two weeks later, the animals were re-operated on, all 
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electrophysiological measurements were repeated and, at sacrifice, the heart was 
perfusion fixed for identifying the infarcted portion of the ventricle. 
Finally, in 30 rats assigned to the MI+GF, MI+V and SO+V groups, two weeks 
after GF/V injection the heart was excised and frozen for Molecular Biology analyses 
(MB rats, Table 1) which included electrophoretic and immunoblot assays (5 MI+GF 
and 5 MI+V animals) and quantitative RT-PCR measurements (9 MI+GF, 8 MI+V and 
3 SO+V animals). 
The details of the procedures employed in the study are described below. 
 
A3. Telemetry-ECG recording. 
A3.1 ECG telemetry System. 
The radiotelemetry system consisted of a miniaturized transmitter for telemetry 
ECG recording (25 x 15 x 8 mm; model TA11CTA-F40, Data Sciences, St Paul, MN, 
USA) and a receiver (model CTR85-SA, Data Sciences, St Paul, MN, USA) which was 
placed under the experimental cage during the recording sessions (Fig. 2) 
A3.2 Chronic instrumentation for telemetry-ECG recording. 
The telemetry ECG transmitter was chronically implanted according to a 
surgical procedure previously published (Sgoifo A et al. 1996). Briefly, the animals 
were anesthetized with ketamine chloride 40mg/kg ip (Imalgene, Merial, Milano, Italy), 
plus medetomidine hydrochloride 0.15 mg/kg ip (Domitor, Pfizer Italia S.r.l., Latina, 
Italy). A ventral celiotomy was performed and the body of the transmitter (25x15x8 
mm) was placed in the abdominal cavity. One recording lead was fixed to the dorsal 
aspect of the xiphoid process, close to the apex of the heart. The other lead was 
subcutaneously tunneled on the thorax toward the upper insertion of the sternohyoid 
Materials and Methods – Protocol A 
 20
muscle. Here, the wire was formed into a U shape, pushed under the muscle and then 
along the trachea into the anterior mediastinum, to get the tip of the recording lead close 
to the right atrium. Finally, the muscle and skin layers were separately sutured. 
After surgery, all animals were given atipamezole hydrochloride 0.15 mg/kg im 
(Antisedan, Pfizer Italia S.r.l.), flunixin 5 mg/kg im (Finadyne, Schering-Plough S.p.a, 
Milano, Italy), gentamicine sulphate 10 mg/kg im (Aagent, Fatro, Milano, Italy), and 
kept warm with infrared lamp radiation. Antibiotic therapy was continued in the 
following three days while the animals were individually housed.  
A3.3 Social stress procedure and telemetry-ECG data acquisition and processing. 
Social stress was obtained by resident–intruder test paradigm (Martinez M et al, 
1998) which consists of introducing the instrumented animal (intruder) into the territory 
of an unfamiliar conspecific male (resident) belonging to an aggressive wild strain of 
rats (Rattus norvegicus, Wild Type Groningen, WTG). All experimental session were 
carried out during the light phase, between 9.00 AM and 1 PM. Each session consisted 
of two successive 15-min telemetry ECG recordings which were performed while the 
instrumented animal was respectively: (i) left alone and undisturbed in its home cage 
(baseline conditions) and (ii) exposed to the social stress procedure (test period). During 
the entire recording session, the telemetry ECG receiver (Fig. 2) was placed under the 
experimental cage. ECGs, provided as analog signals at the output of the receiver, were 
continuously monitored on an oscilloscope and simultaneously routed to a personal 
computer via an analog-to-digital conversion board (12 bits, 1000 Hz sampling rate, Fig. 
2). A real-time acquisition program allowed the digital data to be continuously recorded 
and stored on hard disk for off-line processing. The data were then analyzed by using a 
custom made software package for measuring R–R interval, interactively detecting 
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ventricular rhythm disturbances and computing heart rate-based-indices of autonomic 
input to the heart. The indices included the standard deviation of R-R interval (SDRR) 
and the square root of the mean of the squared differences between adjacent R-R 
interval (r-MSSD) taken respectively as indices of cardiac sympathovagal balance and 
vagal input to the heart (Malik M et al. 1995). Ventricular arrhythmic events (VAEs) 
were classified as follows: (i) PVBs: isolated premature ventricular beats, and (ii) 
salvos: episodes of two or three consecutive PVBs (Walker MJA et al. 1988). 
 
A4. Myocardial infarction. 
Rats under ketamine-medetomidine anaesthesia were intubated and artificially 
ventilated (Rodent ventilator UB 7025, Ugo Basile, Comerio, Italy). With the aid of a 
dissecting microscope, a thoracotomy via the third-left intercostal space was performed 
and a 5-0 silk suture was passed with a tapered needle under the left anterior descending 
coronary artery, 2-3 mm from the edge of the left auricle, and tied securely. The 
development of a pale colour in the distal myocardium on ligature, as noted by visual 
inspection, was taken as index of successful performance of coronary occlusion. The 
chest was then closed in layers, and a small catheter was introduced in the thorax to 
evacuate air and fluids. The rats were given atipamezole hydrochloride, removed from 
the ventilator, kept warm with infrared lamp radiation and eventually individually 
housed. Antibiotic therapy was given during the subsequent 3 days, as indicated above. 
Sham-operated rats were treated similarly, except that the ligature around the coronary 
artery was not tied. 
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A5. Intramyocardial injection of HGF+IGF-1 and BrdC delivery.  
Four weeks after coronary ligature, left lateral thoracotomy was repeated in all 
animals under anaesthesia and artificial ventilation as described above. In MI+GF rats 
six injections with increasing concentrations of HGF (PeproTech EC, London, UK) and 
constant concentration of IGF-1 (PeproTech EC) were done. The first injection was 
located near the atria, the second between the atria and the infarct and the last four at 
opposite sites of the border zone. In MI+V and SO+V rats, corresponding regions of the 
heart were injected with vehicle. The sterile solution of growth factors contained 
different concentration of HGF (atria: 50 ng /mL; atria-border zone: 100 ng/mL; 
opposite sides of border zone: 200 ng/mL) and constant concentration of IGF-1 (200 
ng/mL in all six injection sites) diluted in saline (phosphate buffer solution: PBS). In 
MI+GF rats, Rhodamine microspheres, 2.0 μm in diameter (FluoSpheres, Molecular 
Probes, Eugene, USA), were added to the solution (v/v 5%) to ensure the successful 
injection. The volume of each injection was 10 μL. 
Simultaneously to the GF/V injection, in selected subgroups of MI+V and 
MI+GF animals, an osmotic pump (model 2ML4, ALZET, Charles River, Italy) was 
implanted subcutaneously in the interscapular region for continuous infusion of BrdC 
(0.6 mol/L; MP Biomedicals Europe, Asse-Relegem, Belgium) with a delivery rate of 
2.5 μL/h. Infusion was maintained until the animals were killed (15 days). The long 
infusion time prompted us to use BrdC rather than BrdU because of the nearly six fold 
higher solubility of BrdC. 
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A6. Echocardiographic measurements.  
Serial echocardiograms were obtained in rats under ketamine-medetomidine 
anaesthesia, using a Vivid 7 echocardiography machine (GE Medical Systems, 
Madison,WI, USA) equipped with 10 - 7 MHz phased array transducers The anterior 
chest was shaved and the animals were placed in the left lateral decubitus position. 
Two-dimensional (2-D) and M-mode images were recorded from modified parasternal 
long axis and parasternal short-axis views. Diastolic and systolic anatomical parameters 
were obtained from M-mode tracings at the mid-papillary level. The measurements 
included: (i) end-diastolic and systolic left ventricular diameter (LVEDD and LVSD, 
respectively); (ii) end-diastolic and end-systolic left ventricular volume (LVEDV, 
LVESV), and (iii) ejection fraction and fractional shortening (EF, FS). Data were 
analyzed by an investigator who was blind to the treatment  
 
A7. Hemodynamic studies.  
Rats were anesthetized with droperidol + fentanyl citrate (Leptofen, Farmitalia-
Carlo Erba, Milan, Italy; 1.5 mg/kg im) which we have found to induce negligible 
changes in hemodinamic parameters as measured in conscious animal by means of 
telemetry recording (unpublished data). The right carotid artery was cannulated with a 
microtip pressure transducer catheter (Millar SPC-320, Millar Houston, TX, USA) 
connected to a recording system (Power Laboratory ML 845/4 channels, 2Biological 
Instruments, Besozzo-Varese, Italy) and systolic and diastolic blood pressure were 
determined. The catheter was then advanced into the left ventricle to measure: (i) left 
ventricular systolic (LVSP) and end-diastolic pressure (LVEDP) and (ii) maximum rate 
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of ventricular pressure rise (+dP/dt) and reduction (-dP/dt) in the closed-chest 
preparation. (software package CHART B4.2). 
 
A8. Epicardial multiple-lead recording       
Each rat  under ketamine - medetomidine anaesthesia and artificially ventilated 
was subjected to left thoracotomy. Body temperature was held constant at 37°C by 
infrared lamp radiation. A 5x5 or 8x8 row and column electrode array, fabricated on a 
surgical gauze patch, with 1 mm resolution square mesh, was positioned on the 
infarcted region and the surrounding areas with the upper border of the array just below 
the site of coronary ligature (Fig. 3a-b). The construction of the electrode array and the 
multiple lead recording system have been described in detail before (Macchi E et al. 
1998). The following measurements were carried out: 
A8.1 Conduction velocity.  
In each experiment, 64 unipolar electrograms (EGs) were recorded during 
normal sinus rhythm (SR) or ventricular pacing at 8 selected electrodes of the array 
(Fig. 3c), by near-threshold, ≤1 ms cathodal current pulses, at a frequency slightly 
higher than spontaneous SR (≈ 300 bpm). During pacing, unipolar EGs were recorded 
from all the electrodes except at the paced site (Fig. 3d). Activation times were 
estimated using the instant of the minimum time derivative of unipolar EGs during 
QRS, and were referenced to QRS onset or stimulus onset. From the activation times of 
paced beats an activation sequence (isochrone map) was determined where Conduction 
Velocity (CV) was computed longitudinally (CVl) and transversally (CVt) to fiber 
orientation (Fig. 3e). Specifically, CVl was evaluated from electrodes distant from the 
pacing site on the long axis of the elliptical wavefront. CVt was evaluated from 
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electrodes on a line perpendicular to the long axis of the elliptical wavefront across the 
more closely spaced isochrones. It is known that the long axis of the elliptical wavefront 
is parallel to the local fiber direction at the pacing site (Taccardi B et al. 2008)  
A8.2 Excitability. 
Eight selected electrodes of the array (see above) were initially paced with 
current pulses of decreasing strength (starting from liminar values) at a constant width 
of 5 ms till activation failed, thus identifying threshold current (Ith). The procedure was 
repeated with current pulses of progressively shorter width, up to 0.01 ms. The 
threshold currents as a function of pulse duration define the strength-duration (S-D) 
curve (Fig. 3f) which is represented by the hyperbolic equation (Lapicque L 2007) 
relating threshold current strength I and pulse duration T: 
 
where Rh is the rheobase (i.e. the lowest intensity with infinite pulse duration which 
succeeds in eliciting a propagated response in excitable tissues) and Chr the chronaxie 
(i.e. the pulse duration having a threshold intensity of twice Rh). The two parameters 
which univocally identify the S-D curve, characterize tissue excitability (Fig. 3f). 
A8.3 Refractoriness.  
At each of the 8 selected electrodes of the array (see above), 10 baseline stimuli 
(S1), 1 ms width and twice diastolic threshold intensity, were delivered at a pacing 
cycle length of 300 ms. The S1 pacing sequence was followed by an extra-stimulus (S2) 
whose delay from previous S1 was first progressively decremented by 10ms steps until 
capture was lost and then progressively incremented by 2 ms steps till capture was 
resumed. The longest S1-S2 coupling interval that did not originate ventricular capture 
I = Rh (1+ Chr  ) 
T 
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identified the effective refractory period (ERP) at a given electrode site, enabling the 
characterization of spatial differences in tissue refractoriness. 
A8.4 Dispersion of refractoriness.  
The degree of dispersion was evaluated by computing ERP dispersion value 
taken as basic indicator of propensity to re-entrant arrhythmias (Opthof T et al. 1993). 
In an individual animal ERP dispersion was expressed by the standard deviation of the 
mean ERP at all test sites (Ogawa S et al. 1991). 
A8.5 QT interval duration. 
In each animal, the duration of QT and corrected QT interval (normalized to 
cycle length: QTc) (Mitchell GF et al. 1998) was measured from the root mean square 
(RMS) signal computed from all the 8x8 EGs and represented the average of 4 
randomly selected beats. The RMS provides a composite measure of all electrical 
activity as a single positive-magnitude average of signals obtained from multiple 
unipolar EGs simultaneously (Fuller MS et al. 2000), greatly improving the signal to 
noise ratio. QT duration was computed as the interval between QRS onset and the time 
of the minimum of the first derivative of RMS signal, during the descending limb of T-
wave (Lux RL et al.  2006). 
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A9. Cardiac anatomy. 
The abdominal aorta was cannulated, the heart was arrested in diastole with 
injection of CdCl2 solution (100 mmol/L iv), and the myocardium was retrogradely 
perfused with 10% buffered formalin solution. The left ventricular chamber was filled 
with fixative at a pressure equal to the in vivo measured systolic pressure. 
The heart was then excised and placed in formalin solution (10%) for 24 hours. 
The right ventricle (RV) and the left ventricle (LV) inclusive of the septum were 
separately weighed and the volume of the left ventricular myocardium was computed by 
dividing LV weight by the specific gravity of the tissue (1.06 g/mL). LV chamber 
length was measured from the apex to the aortic valve. Three 1-mm-thick transverse 
slices were cut from the base, mid-region, and apex of the LV. The mid-slice was used 
to measure LV wall thickness and chamber equatorial diameter (Image Pro-plus, Media 
Cybernetics, Bethesda, USA). The LV chamber volume was computed according to the 
Dodge equation (Dodge HT et al. 1969). The three slices were then embedded in 
paraffin and from each slice five-micrometer-thick sections were cut and used for 
morphometric and immunohistochemical analyses. 
 
A10. Morphometrical analysis. 
A10.1 Collagen accumulation in the spared LV.  
Five-micrometer-thick sections from the equatorial slice of the LV (see above) 
were stained with Masson’s trichrome and analyzed by optical microscopy 
(magnification 250X) in order to evaluate in the remote spared myocardium: (i) the 
volume fraction of myocytes, (ii) the volume fraction of fibrosis, and (iii) the numerical 
density and average cross-sectional area of fibrotic foci. Quantification of myocardial 
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scarring resulting from focal myocyte cell loss were included in the analysis since foci 
may represent an important ongoing post-infarction tissue injury. According to a 
procedure previously described (Stilli D et al. 2007), for each section, a quantitative 
evaluation of the volume fraction of myocytes and fibrotic tissue was performed in 60 
adjacent fields from sub-endocardium, mid-myocardium and sub-epicardium. The 
measurements were obtained with the aid of a grid defining a tissue area of 0.160 mm2 
and containing 42 sampling points each covering an area of 0.0038 mm2. 
A10.2 Infarct Size. 
In MI animals, the area of the damaged tissue from the endocardial to the 
epicardial layer and the total area of the viable myocardium were measured in the three 
slices corresponding to the base, mid-region and apex, indicated above. Due to 
shrinkage of the infarcted region and ongoing myocyte growth and death within the 
viable myocardium, the computation of the number of lost and remaining myocytes 
after infarction provides a more appropriate characterization of infarct size and extent of 
recovery with time.  The number of myocytes in the LV of control and infarcted hearts 
was obtained by employing a methodology well-established in our laboratory (Olivetti 
G et al. 1991; Orlic D  et al. 2001a). The quotient between the number of myocytes 
present in the infarcted LVs and the number of LV myocytes in sham-operated animals 
gives the percentage of myocytes lost after infarction. The percentage of myocytes lost 
provides a quantitative measurement of infarct size, while the percentage of myocytes 
left correlates with ventricular function. The newly-formed myocardium in treated 
hearts was not included in this analysis, in order to evaluate the consequences of 
coronary ligature on infarct size independently of tissue reconstitution. 
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A10.3 Myocyte Cell Size.  
In sections of 7 SO+V, 10 MI+V and 12 MI+GF hearts obtained from as many 
randomly selected TE rats, the cross-sectional area of myocytes was morphometrically 
determined by measuring the cell diameter, at the nucleus level, in transversally oriented 
myocytes. For each heart, 120 to 250 cellular measurements were performed. 
 
A11. Immunohistochemical analysis.  
Five-micrometer thick sections (see above), obtained from rat hearts treated with 
BrdC and exhibiting comparable infarct size, were analyzed to determine: (i) the 
expression and spatial distribution of connexin43 (Cx43) and N-cadherin, (ii) the 
incidence of c-kit+ CPCs, and (iii) the fraction of nuclei labeled by BrdU, in the 
infarcted, peri-infarcted and remote LV myocardium. The quantification of BrdU 
labeling in arterioles was not included in the study because the procedure does not allow 
us to assess the fraction of newly formed structures, which are constituted by a multiple 
layer of cells. BrdU, c-kit, Cx43 and N-cadherin labeling was detected by 
immunofluorescence. LV sections were incubated with the primary antibody 
(monoclonal mouse anti-BrdU antibody, dilution 1:20, Dako, Glostrup, Denmark; rabbit 
polyclonal anti-c-kit antibody, dilution 1:20, Santacruz Biotecnology, Inc, Santa Cruz, 
CA, USA; mouse monoclonal anti-Cx43 antibody, dilution 1:250, Chemicon, 
Temecula, CA, USA; rabbit polyclonal anti-N-cadherin antibody, dilution 1:200, 
Calbiochem, San Diego, CA, USA). Myocytes, smooth muscle cells and endothelial 
cells were identified by staining the same sections respectively with monoclonal mouse 
anti-asarcomeric actin antibody (anti-α-SARC; dilution 1:30, Dako), monoclonal mouse 
anti-a-smooth muscle actin antibody (anti-α-SMA; dilution 1:50, Dako), and polyclonal 
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rabbit anti-vW factor (dilution 1:100, Dako) respectively. FITC-, TRITC- Cy5- 
conjugated anti-mouse or anti-rabbit secondary antibodies (Jackson Laboratory, 
Baltimore, PA, USA) were used to detect simultaneously the different epitopes. Nuclei 
were recognized by  DAPI (4',6-diamidino-2-phenylindole) staining.  The amount of 
newly formed myocardium was computed by calculating the number and size of small 
a-SARC+ myocytes according to a methodology previously employed (Orlic D et al. 
2001a). The number of resistance arterioles was measured by counting vascular profiles 
labeled by α-SMA, within the infarcted myocardium. 
 
A12. Electrophoretic and immunoblot analysis. 
The infarcted and non-infarcted portions of the LV ventricles were weighed and 
immediately frozen at -80 °C. For immunoblot assay of Cx43, the fresh ventricular 
tissue was lysed with 150-200 mL of lysis buffer containing the following (SIGMA, St 
Louis, MO, USA): protease inhibitor dithiothreitol (0.5 mmol/L), DNase (50 mg/mL), 
RNase (50 mg/mL), HEPES (10 mmol/L), NaCl (400 mmol/L), EGTA (0.1 mmol/L), 
glycerol (5%), NP40 (3%). Equivalents of 100-125 mg of protein were separated by 
10.5% SDS-PAGE, transferred on nitrocellulose filters and exposed to anti-Cx43 
monoclonal mouse antibody (dilution 1:750, Chemicon). Binding sites were detected by 
peroxidase-conjugated specific anti-mouse IgG (dilution 1:2000, in ECL reagents; 
Amersham Biosciences, Piscataway, NJ, USA). The intensity of the bands representing 
the connexin protein was quantified using a densitometer (Molecular Dynamics, 
Sunnyvale, CA, USA) and the data were expressed as optical density units. 
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A13. Real-Time RT-PCR: Quantification of Kv (α) and accessory subunits. 
Immediately after death, the LV and RV were excised from the heart; each 
sample was frozen in liquid nitrogen, and stored at -80°C. Total RNA from each cardiac 
sample was isolated and DNasetreated with the RNeasy Fibrous Tissue Mini Kit 
(Qiagen, Milan, Italy) following the manufacturer's instructions. Isolated RNA was 
quantified (spectrophotometric absorbance at 260 nm) and purity was confirmed by the 
A260/A280 ratio. Integrity of total RNA was evaluated by ethidium bromide staining on 
denaturing agarose gels. RNA samples were stored at -80°C.  
A13.1 Reverse transcription.  
Single-stranded cDNA was performed by using High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA, USA) following the 
manufacturer's instructions. The reverse transcription reaction was performed by 
incubating a reaction mixture containing: 2 μg RNA, 10X RTBuffer, 10X RT-random 
primers, 25X dNTP Mix (100 mmol/L), RNase inhibitor, and Multiscribe Reverse 
Transcriptase in a total of 20 μL 1X reaction buffer. Reverse transcription was 
performed at 25°C for 10 min, 37°C for 120 min and stopped by incubating at 85°C for 
5s.  
A13.2. Real-Time RT-PCR.  
Expression levels of Kv1.4, Kv4.2, Kv4.3 and KChiP2 genes were investigated 
using real-time quantitative RT-PCR and TaqMan® probe-based chemistry. When 
evaluated by the same method, the gene GAPDH showed stable expression in the LV 
and RV under all of the experimental conditions and was therefore used as endogenous 
control gene. Primers and probes were obtained from ABI (Applied Biosystems, Foster 
City, CA, USA) TaqMan Gene Expression Assay catalogue. These assays come in a 
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20X reaction mix, span an exon-exon junction, and are optimized to give approximately 
100% efficiency. The realtime RT-PCR reactions were performed using TaqMan® 
Gene Expression Master Mix (Applied BioSystems) in a 20 μL reaction volume 
containing 50 ng of cDNA. All reactions were performed in triplicate and included a 
negative control. PCR reactions were carried out using an ABI Prism 7500 Sequence 
Detection System (Applied Biosystems). Cycling conditions were: 2-min at 50°C, 10-
min at 95°C, and 40 cycles of 15 s at 95°C and 1-min at 60°C. Relative quantification of 
mRNA levels was obtained by the 7500 system software, which uses the comparative 
method (ΔCT). 
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Protocol B: Mobilization of CPCs by HMGB1 injection, in  
acute myocardial infarction.  
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B1. HMGB1 Production.The purified High-mobility group box 1 protein (HMGB1) as 
well as its inactive truncated form (boxA) were provided by Laboratorio di Patologia 
Vascolare, Istituto Dermopatico dell’Immacolata, Istituto di Ricovero e Cura a Carattere 
Scientifico, Rome, Italy. 
 
B2. Animals. 
Twenty-three, 4-month old male Wistar rats (Rattus Norvegicus) were used in 
the study. The animals were maintained in groups of 5 individuals and housed in clear 
makrolon cages measuring 55 X 35 X 20 cm, from weaning until telemetry ECG 
transmitter implantation. Animals were always kept in a temperature-controlled room at 
22–24 °C, with the light on between 7.00 AM and 7.00 PM. 
The experimental design and measurements performed in the study are 
summarized in Table 2. 
 
 
B3. Surgical procedure for implantation of telemetry ECG transmitter. 
All animals were chronically instrumented with a miniaturized telemetry ECG 
transmitter (Data Sciences), as described under subheading A3 of protocol A. 
Myocardial infarction was induced 10 days after surgery. 
 
B4. Myocardial infarction and Protein Injection. 
Myocardial infarction was induced in 17 rats, anesthetized with ketamine - 
medetomidine anaesthesia and artificially ventilated, by following the same procedure 
described under subheading A4 of protocol A. The remaining 6 animals were sham-
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operated. The chest was closed and the animals  were allowed to recover. After 4 hours, 
the animals were re-operated and injected with: (i) 2 μg of purified HMGB1 (7 MI rats, 
MI+HMGB1 group) diluted in phosphate buffer solution (PBS), or (ii) 2 μg of inactive 
protein (10 MI rats and 6 sham operated animals: MI+boxA and SO groups). In each MI 
rat, four injections (5 μL per injection) were made in the viable myocardium bordering 
the infarcted area, through a 26-gauge needle. Corresponding regions of the left 
ventricular wall were injected in SO rats (Limana F et al. 2005).  Cardiac electrical 
performance  was evaluated two weeks after surgery. 
 
B5. Evaluation of cardiac electrical performance: telemetry ECG recording 
Two successive 15-min telemetry ECG recordings were performed in baseline 
conditions and during social stress exposure, as described under subheading A3.3 of 
protocol A. The data were then analyzed by using a custom made software package for 
measuring, in the two experimental conditions, the average values of : a) R–R interval, 
b) R-R interval variability indices (SDRR: standard deviation of R-R interval and r-
MSSD: the square root of the mean of the squared differences between adjacent R-R 
interval), and c) number of ventricular arrhythmic events (VAEs).  
 
B6. Infarct size. 
After telemetry ECG recording, the animals were sacrificed. The abdominal 
aorta was cannulated, the heart was arrested in diastole, and the left ventricular chamber 
was perfusion-fixed, as described under subheading A9 of protocol A. Then, the left 
ventricles of MI animals were analyzed to verify the presence and measure the size of 
myocardial infarction (see also subheading A10.2. of protocol A). 
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Statistical analysis. 
The SPSS statistical package was used (SPSS, Chicago, IL, USA, 17th version). 
Normal distribution of variables was checked by means of the Kolmogorov-Smirnov 
test. Statistics of variables normally distributed (all variables except baseline 
arrhythmias) included mean ± standard error (SE), paired and unpaired Student’s t test, 
and one-way analysis of variance (post-hoc analysis: Games-Howell test and Tukey test 
when appropriate). Non-parametric statistical tests were used to evaluate differences in 
the incidence of baseline ventricular arrhythmias among groups (Kruskall-Wallis test 
and Mann-Whitney U-test), and differences between baseline and stressinduced 
arrhythmias within each group (Wilcoxon test). Statistical significance was set at 
p<0.05. 
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Fig.2. ECG Data acquisition  
A- Telemetry ECG transmitter, chronically implanted in each TE animal. 
B - Telemetry ECG, provided as analog signal at the output of the receiver, was routed 
to a personal computer via an analog-to-digital conversion board (12 bits, 1000 Hz 
sampling rate)  
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Fig. 3 Epicardial multiple-lead recording: electrode arrays and procedures. 
a) Electrode array positioned on the anterior aspect of the left ventricular surface.  
b) Schematic representation of the 5x5 (in red) and 8x8 electrode arrays showing the 
positions (larger circles) of the 5 and 8 selected electrodes used for specific pacing 
protocols.  
c) and d): Unipolar electrograms collected by means of the 8x8 electrode array during 
normal sinus rhythm (c) and ventricular pacing at the electrode indicated by the pulse 
symbol (d).  
e): example of paced activation isochrone map used for computing conduction velocity 
longitudinally (blue-arrow) and transversally (red-arrow) to fiber orientation; numbers 
on each isochrone line indicate the activation time in ms.  
f): strength-duration curve obtained in a control rat by plotting pulse threshold current I 
as a function of pulse duration T (Rh: Rheobase, Chr: Chronaxie). 
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Table 1. Outline of the experimental protocol A 
 
In vivo studies 
 
 
day 
 
TE rats (n=60) 
 
EM rats (n=43) 
 
MB rats (n=30) 
     
Chronic instrumentation for telemetry-ECG recording 1 + - - 
Telemetry-ECG recording in baseline conditions 7 + - - 
Myocardial infarction 10 + + + 
Echocardiographic measurements 32 + (selected subgroups) - - 
Telemetry-ECG recording during baseline and social stress 
conditions 
36 + - - 
Epicardial multiple-lead recording 39 - + - 
Intramyocardial injection of  HGF+IGF-1 or vehicle  39 + + + 
Implantation of an osmotic pump for continuous (two weeks) 
BrdC delivery 
39 + (selected subgroups) - - 
Echocardiographic measurements 52 + (selected subgroups) - - 
Telemetry-ECG recording during baseline and social stress 
conditions 
54 + - - 
Epicardial multiple-lead recording 54 - + - 
Hemodynamic measurements  + (selected subgroups) - - 
Sacrifice 60 + + + 
 
Post mortem studies 
    
Anatomical identification of myocardial infarction  + +  
Cardiac anatomy and infarct size  + - - 
Morphometric analysis  + (selected subgroups) - - 
Immunohistochemical analysis  + (selected subgroups) - - 
Electrophoretic and immunoblot analysis  - - + (selected subgroups) 
Quantitative RT-PCR measurements  - - + (selected subgroups) 
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Table 2. Outline of the experimental protocol B  
 
In vivo studies days                                                                          MI+boxA (n=10)   MI+HMGB1 (n=7)   SO n=6
Chronic instrumentation for          
telemetry ECG recording 1              +                             +                           + 
Myocardial infarction 10              +                             +                           + 
Simulate surgery 10                                                                           + 
Intramyocardial injection of  HMGB1  
or truncated form (boxA)               +                             +                           + 
Telemetry ECG recording during      
baseline and social stress 36              +                             +                           + 
Sacrifice 36              +                             +                           + 
Post mortem study   
Infarct size               +                             +                        
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1. Telemetry-ECG recording. 
1.1. R-R interval and R-R interval variability (SDRR and r-MSSD). 
R-R interval, SDRR and r-MSSD during baseline had similar values in all groups 
or exhibited negligible differences (Table 3). Stress procedure, generally, increased 
heart rate by about 30% and reduced SDRR and r-MSSD by about 40% and 30% 
respectively (Table 2)., as a result of the enhanced sympathetic activity brought about 
by the social challenge (Martinez M et al. 1998). The effects of stress were similar 
before and after GF/V injection in each animal group, suggesting that growth factor 
administration did not have affect to autonomic input to the heart.  
1.2. Ventricular arrhythmias.  
Arrhythmia vulnerability was evaluated as the number of ventricular arrhythmic 
events (VAEs) during the 15-minute baseline and stress periods. In all animals, VAEs 
mostly consisted of isolated premature beats and a few salvos (two or three consecutive 
premature beats; Fig. 4a).  
Before GF/V injection, VAEs were negligible during baseline in all groups 
(Table 4). Stress exposure significantly increased VAEs in SO and MI groups but the 
increment was about two-fold higher in MI animals (p<0.05 vs. SO Fig. 4b). Two 
weeks after GF/V injection, baseline-VAEs remained unchanged in all groups (Table 4) 
while stress-induced VAEs were markedly reduced in MI+GF rats (p< 0.02) but not in 
SO+V and MI+V animals (Fig. 5). Thus, cytokine treatment lowered the proneness to 
arrhythmias triggered by stress-induced sympathetic stimulation in conscious animals 
with chronic myocardial infarction. 
Results of protocol A 
  45
2 Ventricular mechanical performance. 
2.1. Echocardiographic measurements. 
Before GF/V injection, a global deterioration in cardiac anatomy and function 
was observed in the MI group when compared with the SO group (Table 5). 
Echocardiographic data measured in MI were characterized by: a) a significant 
reduction (p<0.01) in ejection fraction (EF: -8%) and  fractional shortening (FS: -15 %), 
b) a significant increase (p<0.01) in left ventricular systolic diameter (LVSD: +36%), 
end-diastolic diameter (LVEDD: +15%), left ventricular end-systolic volume (LVESV: 
+188%), and left ventricular end-diastolic volume (LVEDV: +57%). 
Two weeks after injection, in the MI+V animals, the morpho-functional 
properties of the left ventricle either remained unchanged or underwent a slight further 
deterioration (Fig. 6). In contrast, in the MI+GF rats, the treatment was followed by an 
improvement in LVEDD and LVEDV values, which approached those measured in the 
SO+V group (Fig. 6), suggesting a positive effect of GFs on left ventricular remodeling.  
Moreover, in the MI+V group, infarct size (morphometrically determined, see 
below) was negatively correlated with fractional shortening and ejection fraction and 
positively correlated with LVSD and LVESV (p<0.05; Fig. 7 a-d). These correlations 
disappeared in MI+GF group (Fig. 7 a’-d’) further supporting the hypothesis that the 
administration of HGF+IGF-1 induced a partial recovery of ventricular mechanical 
performance. 
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2.2 Hemodynamic measurements. 
Invasive hemodynamic measurements were characterized by a substantial 
reduction in arterial blood pressure, systolic ventricular pressure and peak positive and 
negative ventricular dP/dt in MI+V and MI+GF groups when compared with SO+V 
(Fig. 8). However, the impairment of dP/dt and LVEDP was correlated with post 
mortem determination of infarct size in the MI+V group (Fig. 9 a-b) but not in the 
MI+GF group (Fig. 9 a’-b’). In line with echocardiographic data, these findings confirm 
that GF treatment abolishes the proportional deleterious effect of infarct size on the LV 
mechanical performance.  
 
3 Ventricular electrical performance. 
3.1 Epicardial multiple lead recording. 
To minimize the invasiveness of the surgical procedure and ensure animal 
survival, all pre-GF/V injection measurements were obtained using the 5x5 electrode 
array (Fig. 3b). Instead, the post-GF/V-injection measurements, carried out before 
sacrifice, were performed using the 8x8 array (Fig. 3b) to allow for a wider exploration 
of the epicardial surface. Furthermore, the appropriate positioning on the ventricular 
epicardium of the array was in some cases prevented by an unfavorable spatial 
relationship between heart and lungs in the open chest preparation. Because of this and 
the presence of scattered fibrotic areas in the infarcted region, only a fraction of the 25-
64 sites explored by epicardial electrodes were excitable and/or enabled the recording of 
reliable EG signals. 
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3.1.1  Excitability.  
Globally, 121, 120 and 114 Strength-Duration (S-D) curves and as many 
Rheobase (Rh) and Chronaxie (Chr) values (Fig. 3f) were determined in the MI, MI+V 
and MI+GF groups respectively. Before injection, Rh and Chr in MI animals were 
114±10 μA and 1.2±0.04 ms respectively. Cytokines shifted upward and to the right S-
D curves and concurrently Rh and Chr values in MI+GF rats were slightly higher than 
those measured in MI+V group (Fig. 10a).  
3.1.2. Conduction velocity.  
Given the limited number of electrodes of the 5x5 array, no reliable conduction 
velocity (CV) measurements could be performed in the MI rats and only post-injection 
data were collected in the MI+V and MI+GF groups. CV was computed longitudinally 
(CV-l) and transversally (CV-t) to fiber orientation (Fig. 3e) at 114 and 112 epicardial 
sites in MI+V animals and 92 and 100 sites in MI+GF rats. The values of both CV-l and 
CV-t were similar in the two groups (Fig. 10b), suggesting that growth factor 
administration did not have any sizable effect on the spread of excitation at the 
epicardial surface. 
3.1.3. Refractoriness.  
The effective refractory period (ERP) was measured at 87, 113 and 92 epicardial 
sites in the MI, MI+V and MI+GF animals respectively. In the MI rats the average ERP 
value was 88.8±2.4 ms. After GF/V injection, ERP was about 30% longer in the MI+GF 
animals when compared with the MI+V group (Fig. 10c, p<0.01). A longer ERP would 
reduce the probability of reentry circuits provided that CV increases or remains constant 
(van Rijen HV et al. 2006). Thus, by the combined effect on conduction velocity and 
Results of protocol A 
  48
refractoriness, cytokine treatment is expected to reduce cardiac electrical instability. 
Indeed, stress-induced VAEs were significantly reduced in GF treated animals. 
3.1.4. ERP dispersion and QTc interval duration.  
The degree of dispersion of ERP values and the duration of QTc interval were 
comparable in all animals (Fig. 10 d-e), suggesting that the influence of GFs on 
propensity to reentrant arrhythmias was not mediated by changes in the spatially non-
uniform distribution of refractoriness. Furthermore, the longer ERP in MI+GF animals 
does not seem attributable to the longer duration of the recovery process. 
 
4. Molecular analysis. 
4.1. Electrophoretic and immunoblot analysis: Connexin43 expression. 
Quantification of Cx43 expression was performed by western blot analysis on 
samples of the infarcted and remote portions of the rat hearts. The levels of Cx43 within 
the infarcted region were negligible in the MI+V group (Fig. 11) whereas local GF 
administration increased by about 10-fold (p<0.01) the expression of the gap junctional 
protein, suggesting a better electrical coupling within the scarred partially regenerated 
myocardium. Similar findings, although of lower magnitude (about 30% increase, 
p<0.05), were observed in the remote myocardium (Fig. 11). 
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4.2.Quantitative RT-PCR measurements of Ito current subunits. 
To determine whether an altered modulation of transient outward K current (Ito) 
could affect ERP, the major isoforms of the rat alpha (Kv4.2, Kv4.3, Kv1.4) and beta 
(KChIP2) subunits were measured at mRNA level in the peri-infarcted and remote (left 
and right) ventricular myocardium of the MI+V and MI+GF rats, in comparison with 
SO+V. The mRNA expression for Kv4.2 and Kv4.3 alpha subunits in each myocardial 
region was similar in all animals. Conversely, Kv1.4 and the accessory subunit of the K 
channel KChIP2 were significantly increased by MI, in the remote left and right 
ventricular myocardium (Kv1.4: about +50%, p<0.05) (Fig. 12 a,c), and peri-infarcted 
and remote LV myocardium (KChIP2: about +100% and +20% , p<0.01) (Fig. 12b). In 
both cases, the rise was prevented by cytokines. 
 
5. Cardiac Remodeling. 
5.1. Cardiac Anatomy. 
Compared with the SO+V animals, the MI+V group exhibited a significant 
increase in chamber volume associated with a moderate thinning of the left ventricular 
wall, resulting in a decreased mass-to-chamber volume ratio (Table 6). These markers 
of unfavorable remodeling, representing the major anatomical determinants of heart 
failure, were attenuated in the MI+GF rats (Table 6).  
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5.2. Morphometric Measurements. 
Myocardial fibrosis and small foci of collagen accumulation, uniformly 
distributed throughout the LV wall, were detected in the spared non-infarcted 
ventricular myocardium of both MI+V and MI+GF groups. However, the volume 
fraction of interstitial fibrosis and the number of foci of replacement fibrosis were more 
than 2-fold lower in the treated MI+GF hearts (p<0.01; Fig. 13a-b).  
5.3. Myocyte Cell Size. 
The average cell size was larger in infarcted hearts as compared with the SO+V 
group. However, a statistically significant difference was reached only in the MI+V rats 
(p<0.05 vs. SO+V; Fig. 13c), indicating that reactive cellular hypertrophy was reduced 
by intramyocardial injection of GFs  
5.4. Myocardial regeneration. 
Areas of myocardial regeneration were detected in the infarcted portion of GF 
treated rat hearts. Small BrdU+ myocytes, expressing N-Cadherin (Fig. 14a) and Cx43 
(Fig. 14b) were observed, indicating that newly formed, electromechanically coupled 
cardiac myocytes resulted from local injection of GFs. Within the two weeks from 
cytokine injection a nearly 3-fold increase in cycling myocytes accumulated in MI+GF 
infarcts when compared with the MI+V ones (Fig. 14c). The formation of 
electromechanically competent myocytes was also present in the peri-infarcted and 
remote myocardium of treated animals, suggesting that local delivery of growth factors 
exerted a global beneficial effect on the heart (Fig. 14c). Although similar findings 
could occasionally be detected in untreated chronic infarcts, the quantitative estimation 
clearly indicated that the regenerative processes were markedly enhanced in the MI+GF 
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group in both the peri-infarcted and infarcted areas (Fig. 14c). Importantly, the newly 
formed myocardium was properly perfused, as indicated by the significant increase in 
the density of arteriolar profiles (two-fold) and BrdU+ endothelial cells (five-fold) (Fig. 
14 d-f). 
Infarct size was similar in the two experimental groups in which the average 
values of lost myocytes was approximately equal to 4.5 x 106 . Within the infarcted area, 
cytokine treatment promoted the formation of  an average of 5.9 ± 0.1 x 106 developing 
myocytes ranging in size from 200 to a maximum of 4000 μm3 (Fig. 15a). Most newly 
formed cardiomyocytes had a volume of less than 2000 μm3, although cytokine 
treatment was able to generate a consistent number of cells approaching a volume of 
4000 μm3. Conversely, myocardial repair in untreated infarcts was unremarkable. The 
generation of new myocytes increased linearly with the amount of cell loss in GF 
treated animals. A similar reparative capacity was not observed in untreated rats (Fig. 
15b). The observation that myocardial regeneration was associated with intense 
activation and translocation of resident progenitor cells (Fig. 15c) strongly suggested 
that GF-induced cardiac repair was mediated by a multipotent stem cell population. 
Indeed, in comparison with MI+V, a significant (p<0.01) increase in the incidence of c-
kit+ cells was produced by GFs in the infarcted, peri-infarcted and remote myocardium 
(Fig. 15c).  
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Fig. 4. Ventricular arrhythmic events. 
a) Telemetry-ECG recordings during social stress from representative SO (upper 
tracings) and MI animals (lower tracings) showing the different types and severity of 
ventricular arrhythmic events (VAEs).  
b) Average values ± SE of the number of VAEs occurring in SO and MI groups, during 
stress exposure.  
* p<0.01 vs. SO. 
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Fig. 5. Effects of GF/V injection on the proneness to stress-induced arrhythmias 
Changes in the number of stress-induced VAEs after GF/V injection, in each animal of 
SO+V, MI+V and MI+GF groups. * p<0.02 vs. pre-injection values, within MI+GF 
group. The insert shows the average values±SE of the difference (Δ) between the 
number of VAEs measured before and after GF/V injection, in each experimental group. 
# p<0.01 vs. SO+V and MI+V. 
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Fig. 6. Post-injection echocardiographic measurements 
Mean values ± SE of a) EF, b) FS, c) LVSD; d) LVEDD, e) LVESV and f) LVEDV measured 
15 days after treatment in SO+V, MI+V and MI+GF groups.  
*p<0.01 significant differences between SO+V. 
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Fig. 7. Blunting effect of GF treatment on the correlation between infarct size and 
echocardiographic parameters 
Linear correlations between infarct size and fractional shortening (FS), ejection fraction 
(EF), left ventricular systolic diameter (LVSD) and left ventricular end-systolic volume 
(LVESV), in MI+V (a-d) and MI+GF (a’-d’) animals.  
The statistical significance of correlations was limited to the MI+V group. 
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Fig. 8. Hemodynamic measurements 
Mean values ± SE of a) Systolic arterial blood pressure (BP), b) Diastolic arterial BP, c) 
LVSP, d) LVEDP, e) + dP/dt and f) - dP/dt,  in SO+V, MI+V and MI+GF animals. 
* p< 0.01 significant differences vs. SO+V. 
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Fig. 9. Blunting effect of GF treatment on the correlation between infarct size and 
hemodynamic parameters 
Linear correlations between infarct size and maximum rate of ventricular pressure rise 
(+dP/dt) and left ventricular end-diastolic pressure (LVEDP), in MI+V (a-b) and 
MI+GF animals (a’-b’).  
The statistical significance of correlations was limited to the MI+V group. 
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Fig. 10. Epicardial multiple-lead recording 
The bar graphs illustrate the mean values±SE of: (a) rheobase and chronaxie, (b) 
conduction velocity along (CV-l) and across (CV-t) epicardial fiber direction, (c) 
effective refractory period (ERP), (d) ERP dispersion and (e) QTc interval duration in 
MI (before GF/V injection), MI+V and MI+GF groups (after GF/V injection). 
* p<0.05 vs. MI+V. 
 
Figures and Tables of protocol A 
 60
 
 
 
 
Fig. 11. Quantification of connexin43 protein expression. 
Western blot analysis of connexin43 protein expression in infarcted (I) and remote (R) 
left ventricular myocardium of MI+V and MI+GF hearts. MW=molecular weight 
marker; OD=optical density.  
* p<0.05 vs. MI+V. 
Figures and Tables of protocol A 
 61
 
 
 
Fig. 12. Expression of K channel isoforms 
Quantification of Kv1.4 (a, c) and KChIP2 (b) m-RNA levels, in ventricular 
myocardium. PI: peri-infarcted; Remote: spared left ventricular myocardium. Each bar 
represents the mean of 4 different samples in triplicate.  
* p<0.05 vs. SO+V and MI+GF. 
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Fig. 13. Myocardial fibrosis and left ventricular myocyte size 
Mean values±SE of volume fraction of fibrosis (a), and numerical density of fibrotic 
foci (b), morphometrically evaluated in the remote left ventricular (LV) myocardium of 
MI+V and MI+GF hearts. In (c), mean values±SE of the LV myocyte cross-sectional 
area.  
* p<0.05 vs. MI+GV;    
# p<0.05 vs. SO+V. 
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Fig. 14. Myocyte and Vessel Regeneration 
Immunofluorescence staining of sections of the infarcted (a,b,d) myocardium of GF 
treated rats. Arrowheads indicate BrdU labeled (a-b, pink fluorescence) nuclei of small 
α-sarcomeric actin positive cardiomyocytes (α-SARC, green fluorescence) showing in 
red fluorescence mechanical (a, N-cad=Ncadherin) and electrical (b, Cx43=connexin43) 
connections. Blue fluorescence corresponds to DAPI labeling of nuclei. Scale Bars: a) 
20μm; b) and d) 50μm. Bar graphs illustrate the quantification of proliferating 
cardiomyocytes (c) in the infarcted (I), peri-infarcted (PI) and remote myocardium of 
vehicle (V) and Growth Factor (GF) treated hearts. * p<0.05 vs. MI+V. 
Bar graphs illustrate the quantification of (e) the absolute number of arterioles in the 
infarcted (I) myocardium, and of (f) endothelial cells in the peri-infarcted (PI) and 
remote myocardium of vehicle (V) and Growth Factor (GF) treated hearts.  
* p<0.05 vs. MI+V. 
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Fig. 15. Quantitative analysis of cardiomyocyte loss and regeneration, and 
progenitor cell mobilization  
a) Size distribution of newly formed cardiomyocytes in the infarcted area; b) correlation 
between  number of lost cells and newly  formed myocytes; c) density of c-kit+ cardiac 
progenitors in the infarcted, peri-infarcted (PI) and remote myocardium.  
In bar graphs data are reported as mean values±SE for treated and untreated MI animals. 
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Table 3. Mean values ± SE of R-R interval, and R-R interval variability indices (SDRR and r-MSSD) 
measured in baseline and stress conditions in the various experimental groups, before and after GF/V 
injection. 
       Before GF/V injection   After GF/V injection 
 SO 
(n=15) 
MI  
(n=45) 
SO+V 
(n=15) 
MI+V 
(n=23) 
MI+GF 
(n=22) 
   R-R interval (ms) 
baseline 
social stress 
170 ± 5.3 
123 ± 2.9 § 
172 ± 3.5 
120 ± 1.0 § 
182±.5.8 
123 ±.2.4 § 
167 ± 4.8 # 
122 ±1.2 §  
SDRR (ms) 
baseline 
social stress  
r-MSSD (ms) 
baseline 
social stress 
11.0 ± 0.4 
  7.2 ± 0.8 § 
 
3.7 ± 0.3 
2.7 ± 0.2 § 
10.7 ± 0.6 
  5.7 ± 0.4 § 
 
4.9 ± 0.3  
3.0 ± 0.l § 
 
10.3 ± 0.7 
  6.4 ± 0.9 § 
 
4.0 ± 0.4 
2.9 ± 0.3 § 
 
9.9 ± 0.5 
5.2 ± 0.4 § 
 
4.3 ± 0.3 
3.3 ± 0.2 § 
 
183 ±4.8  
125 ±1.8 § 
 
11.7 ± 0.7 
  6.5 ± 0.7 § 
 
5.0 ± 0.4 
3.3 ± 03 § 
 
§ p<0.01 significant differences vs. baseline, within each group; # p<0.05 significant differences vs. 
SO+V and MI+GF. 
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Table 4. Ventricular arrhythmic events  during baseline 
 
 
 Before  GF/V injection After  GF/V injection 
 
Groups 
(number of animals) 
SO 
(15)        
MI 
(45) 
SO+V 
(15) 
MI+V 
(23) 
MI+GF 
(22) 
 
PVBs (range) 
 
(0-1) 
 in 1 rat  
 
(1-6) 
 in 5 rats 
 
 
none 
 
(1-2) 
 in 4 rats 
 
(1-19) 
 in 5 rats 
Salvos (range) none (0-1)  
in one rat 
none none none 
 
number of animals  
without arrhythmias 
 
14 out of 
15  
 
39 out of 45 
 
all rats 
 
19 out of 
23 
 
17 out of 22 
 
PVBs: premature ventricular beats; Salvos: 2-3 consecutive premature ventricular beats. 
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Table 5. Pre-injection echocardiographic measurements 
 
Pre-injection 
 
SO (n=9) MI (n=38) 
EF (%) 89.5±0.9 82.4±1.2 * 
FS (%) 54.8±1.4 46.8±1.2 * 
LVSD (mm) 2.5±0.1 3.4±0.1 * 
LVEDD (mm) 5.5±0.2 6.3±0.2 * 
LVESV (µL) 42±8 121±5   * 
LVEDV (µL) 397±43 625±44 * 
 
Mean values±SE of echocardiographic parameters measured before GF/V injection in SO and 
MI groups.  
EF: ejection fraction; FS: fractional shortening; LVSD: left ventricular systolic diameter; 
LVEDD: left ventricular end-diastolic diameter; LVESV: left ventricular end-systolic volume; 
LVEDV: left ventricular end-diastolic volume.  
*p<0.01 significant differences between SO and MI 
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Table 6. Mean values ± SE of left ventricular (LV) geometrical properties 
measured  in SO+V, MI+V and MI+GF groups.  
 
 SO+V (n=15) MI+V  (n=17) MI+GF  (n=21) 
 
LV mass (mm3) 
 
769 ± 43 
 
 1046 ± 35 * 
 
1031 ± 17 * 
LV wall thickness (mm) 2.2  ± 0.1 2.0 ±0.1 2.2 ± 0.1 
LV chamber diameter (mm) 5.5  ± 0.2    7.2 ± 0.2 *    6.7 ± 0.2 * 
LV chamber volume (mm3) 199 ± 11  413 ± 25 *     336 ± 18 * # 
mass/chamber volume 4.1 ± 0.1    2.4 ± 0.1 *    2.9 ± 0.2 * 
Infarct size (%) __       19.4 ± 3.2      19.9 ± 2.9 
 
* p< 0.01 significant differences vs. SO group; # p< 0.05 significant differences 
between  MI+V and MI+GF.  
Results  
 69
 
 
 
 
 
 
 
 
 
 
 
 
Results of protocol B 
Results of protocol B 
  70
Telemetry-ECG recording 
Hear rate and R-R interval variability (SDRR and r-MSSD.) 
During baseline, the average values of heart rate and heart rate variability 
indexes did not show any significant differences among groups (average values: heart 
rate approximately 350 bpm, SDRR 11.4 ms and r-MSSD 5.4 ms). As expected, in all 
groups the exposure to social stress significantly increased heart rate (+ 39%, on 
average) and reduced SDRR (-45%) and r-MSSD (-43%). Thus, intramyocardial delivery 
of  HMGB1 protein as well as its inactive form did not markedly affect heart rate and 
the autonomic modulation of  heart rate (Fig. 16).  
Cardiac arrhythmias.  
Arrhythmia vulnerability was evaluated as the number of ventricular arrhythmic 
events (VAEs) during the 15-min baseline and stress periods.  
In comparison with SO, MI+boxA rats showed a significantly higher number of 
VAEs during both baseline and stress conditions (p<0.01; Fig.17). The increased 
proneness to arrhythmias was completely abolished in HMGB1-treated MI animals 
(Fig. 17), suggesting a protective effect of protein injection against spontaneous 
arrhythmias as well as arrhythmias triggered by sympathetic stimulation. 
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Fig. 16. R-R interval  and R-R interval variability (SDRR and r-MSSD) 
Average values ± SE of  (a) R-R interval, (b) SDRR and (c) r-MSSD during baseline and 
social stress periods ,in the different experimental groups. 
* Significant differences between baseline recording periods within each group. 
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Fig. 17. Ventricular arrhythmic events 
Average values ± SE of the number of ventricular arrhythmic events (VAEs) during baseline and 
social stress periods, in each experimental group 
* p<0.05 vs.SO  
# p<0.05 vs.MI+HMGB1  
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 During the last decade, a growing number of experimental and clinical 
observations have shown that therapies based on the mobilization/injection of stem cells 
of different origins can ameliorate the mechanical function and perfusion of the ischemic 
heart (Dimmeler S et al. 2005; Leri A et al. 2005). On the other hand, the induction or 
exacerbation of arrhythmias remains a major concern in stem cell based therapies for 
cardiac repair, and the effect of regenerative treatments on cardiac electrogenesis is still 
under debate (Chen HS et al. 2009; Ly HQ et al. 2009; Macia E et al. 2009; Smith RR et 
al. 2008). The present research work specifically addressed this issue, in rat models with 
chronic or acute myocardial infarction.  
 Globally, data reported here support the hypothesis that mobilization of cardiac 
progenitor cells (CPCs)  via intra-myocardial delivery of either GFs (HGF+IGF-1, 
chronic MI) or HMGB1 protein (acute MI), a mediator of the inflammatory response,  
leads to a significant decline in proneness to ventricular arrhythmias. 
The results of the two experimental studies will be separately discussed. 
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A) STUDY ON CHRONIC MYOCARDIAL INFARCTION 
 Our results demonstrate that intra-myocardial injection of HGF and IGF-1 in a rat 
model of healed myocardial infarction caused a significant decline in proneness to 
ventricular arrhythmias, recorded in conscious freely moving animals subjected to 
stressful conditions. A potential underlying mechanism involved in this protective effect 
is the prolongation of the effective refractory period (ERP) at the epicardial surface of the 
regenerated heart, in the absence of changes in dispersion of refractoriness and duration 
of ventricular repolarization, as suggested by measurements of QTc interval and mRNA 
levels for K-channel α-subunits Kv4.2 and Kv4.3. Furthermore, markers of 
cardiomyocyte reactive hypertrophy, including mRNA levels for K-channel α-subunit 
Kv1.4 and β-subunit KChIP2, interstitial fibrosis and negative structural remodeling were 
significantly reduced in peri-infarcted/remote ventricular myocardium of GF-treated 
animals.  
In support of previous data (Linke A et al. 2005, Urbanek K et al. 2005; Rota M 
et al. 2008), we also found that resident CPCs, stimulated locally by GF treatment, 
invaded the scarred myocardium and generated new electromechanically-connected 
myocytes and vessels. Experimental evidence was provided for a partial recovery of 
mechanical competence in the regenerated heart associated with an attenuation of 
unfavorable structural remodeling which involved the peri-infarcted and remote 
myocardium, suggesting that local delivery of GFs also exerted beneficial effects in the 
spared tissue.  
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Recovery of Electrical Function 
Experimental studies aimed at assessing the proarrhytmic/antiarrhythmic potential of 
stem cell based therapies in vivo have been carried out mostly in anesthetized animals and 
in few cases in conscious animals during baseline conditions (Kolettis TM 2006).  However,  
anesthesia can have confounding effects and the incidence of arrhythmias in baseline 
conditions is generally low. To circumvent these limitations, the proneness to arrhythmias 
was evaluated in conscious freely moving rats subjected to the resident-intruder test 
(Martinez M et al. 1998) which mimics stressful conditions encountered by social animals 
in every day life. The procedure is known to consistently induce an intense activation of the 
autonomic nervous system, with a shift of the sympatho-vagal balance towards a 
sympathetic predominance, resulting in arrhythmias even in normal animals (Stilli D  et al. 
2004). Stress-induced ventricular arrhythmias were reduced by about half following GF 
injection while no changes were observed in untreated rats, indicating a protective effect of 
local delivery of cytokines.  
It has been recently reported (Ly HQ et al. 2009)  that important issues to 
consider when assessing the effect of stem cell based myocardial regeneration on 
cardiac electrical competence include: (i) intrinsic electrophysiological properties of 
stem cells, (ii) modulated graft-host and/or graft-graft electromechanical coupling, (iii) 
changes in ion channel function, (iv) induced heterogeneity, and (v) altered myocardial 
tissue architecture comprising heterogeneous sympathetic nerve sprouting. All these 
factors may affect cardiac electrogenesis either by acting alone or in concert with the 
arrhythmic substrate of the injured myocardium. 
We found that dispersion of refractoriness was similar in treated and untreated 
animals, as were the indirect indexes of autonomic input to the heart (SDRR and r-
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MSSD), suggesting that GFs did not alleviate arrhythmia susceptibility by affecting 
repolarization heterogeneity (Fukushima S et al. 2007) or cardiac sympathetic activity 
(Pak HN et al. 2003). 
Quantitative RT-PCR analysis of the genes encoding the Ca2+-independent transient 
outward potassium current (Ito), revealed that transcript expression of Kv1.4 was up-
regulated in remote left ventricle only in untreated rats. Kv1.4 is the main channel subunit 
contributing to Ito during embryonic development of mouse and rat. After birth, Kv1.4 
expression levels decrease, while Kv4.2 and Kv4.3 are up-regulated (van der Heyden MA et 
al. 2006). Importantly, cardiac hypertrophy induces a re-expression of Kv1.4 mRNA 
(Marionneau C et al. 2008). Further, the rise in mRNA levels of potassium channel β-
subunit KChIP2 produced by myocardial infarction was abolished by GF administration. 
Recent studies documented higher mRNA levels of KChIP2 in cardiac hypertrophy 
(Tozakidou M et al. 2010) although a full appreciation of this result is impossible, since to 
date the role of KChip(s) subunit(s) has not been clearly elucidated. In conclusion, the lower 
mRNA levels of Kv1.4 and KChIP2 subunits produced by GF injection might be associated 
with the reduced reactive cellular hypertrophy following cardiac repair. These findings, 
together with anatomical and morphometric data, indicate that GF treatment may succeed in 
partially controlling endogenous arrhythmic substrates by limiting the unfavorable LV 
remodeling, and reducing myocardial fibrosis and reactive cellular hypertrophy in the 
remote myocardium, thereby contributing to prevent the occurrence of re-entry circuits. 
 By using epicardial multiple-lead recording, we showed that cytokine injection 
resulted in a marked prolongation of ERP, while conduction velocity (CV) was 
unchanged. The combined effect of CV and ERP on impulse propagation is defined by 
the wavelength L = CV x ERP, implying that a longer L (by increasing CV and/or 
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ERP) will reduce the likelihood that a single or multiple reentrant circuits can be 
accommodated by the heart (van Rijen HV et al. 2006). Hence, ERP changes observed 
in GF treated rats could reduce the ability of cardiac tissue to elicit an abnormal 
propagated response by increasing L, thus hampering reentry. The finding that 
epicardial QTc values were similar in all animals indicates that mechanisms other than 
lengthening of action potential duration (APD) were responsible for the longer ERP in 
GF treated rats. Accordingly, either membrane currents affecting APD were not 
influenced by GFs or, if they were, the net modification might not be large enough to 
manifest itself at the tissue level. Indeed, our data show that mRNA levels of the 
potassium channel α-subunits Kv4.2 and Kv4.3 did not exhibit any significant 
difference between untreated and HGF+IGF-1 treated hearts, suggesting that the 
transient outward potassium current (Ito), which contributes conspicuously to determine 
APD, was unaltered. 
On the other hand, recent studies have demonstrated that IGF-1, alone or in 
combination with other growth factors, increases Cx43 expression in cardiac myocytes 
(Hahn JY et al. 2008). In support of these findings, we showed that GF administration 
significantly increased the expression of the gap-junctional protein Cx43, providing 
evidence for an increased electrical coupling within the scarred, partially regenerated 
myocardium as well as in the remote spared tissue. A better intercellular electrical 
connection is considered as being an important antiarrhythmic factor (Hahn JY et al. 
2008; Kuhlmann MT et al. 2006; Mills WR et al. 2007; Roell W et al. 2007; Duffy HS 
2008; Gepstein L et al. 2010; Wang D et al. 2010) and could also result in ERP 
prolongation. It has been remarked (Fozzard HA 2001) that the amount of current 
needed for cardiac excitation by point stimulation is modulated by the properties of 
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electrical coupling of the interconnected myocytes via gap-junctions. The smallest 
myocardial region capable of initiating a propagated action potential (“liminal length”) 
is inversely related to the extra- and intracellular resistivities, which are largely 
dependent on interstitial fibrosis and electrical coupling between myocytes respectively 
(Fozzard HA et al. 1972; Fozzard HA 2001). 
The role of myocardial geometry in the charge threshold for excitation was 
documented by computing the S-D curve, which shifted to the right when the “liminal 
length” increased (i.e. reduced excitability) and to the left when it decreased (i.e. 
increased excitability) (Fozzard HA et al. 1972). Changes in “liminal length” resulting 
from different degrees of electrical coupling between myocytes are also expected to 
affect cardiac refractoriness, which will be increased by an increase in “liminal length” 
and reduced by its reduction. Concurrently, the longer ERP and the associated 
tendential shift to the right of the S-D curve induced by HGF+IGF-1 administration 
might be attributed to the higher expression of Cx43 and the longer “liminal length” 
resulting from an enhanced cardiomyocyte interconnection. 
 
Cardiac Regeneration, ventricular remodeling and recovery of mechanical 
function 
Recent studies in animal models of chronic myocardial infarction (Rota M et al. 
2008) have documented a negative impact of the scarred myocardium on the migration 
and engraftment of CPCs when compared with acute infarcts. Yet, GF-activated CPCs 
retain the ability to infiltrate the scar, digest part of the connective tissue, and form 
cardiomyocytes and coronary vessels via enhanced activity of metalloproteases. In 
support of these findings (Rota M et al. 2008), we showed that HGF and IGF-1 
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administration triggered the proliferation and mobilization of CPCs, leading to newly 
formed functionally competent myocardial tissue. Importantly, proliferating myocytes 
expressed N-Cadherin and Cx43 and linearly increased with the amount of cell loss. 
Coronary arterioles and capillary structures were concurrently produced with 
myocytes, tending to preserve blood supply and oxygen diffusion to the surrounding 
cells. Ultimately, GF-induced activation of CPCs elicited a sustained regenerative 
response that resulted in a 20% rescue of the infarct by replacing fibrotic tissue with 
viable myocardium. GF treatment attenuated ventricular dilation, increased ventricular 
mass/chamber volume ratio, and reduced collagen accumulation in the spared 
myocardium more than 2-fold while restraining the hypertrophic response of myocytes 
to the segmental loss of cells. 
As shown by the echocardiography findings, post-MI ventricular dysfunction 
tended to recover in GF treated infarcts. Furthermore, echocardiographic and 
hemodynamic data documented that the significant, negative correlation of cardiac 
mechanical function with the extension of the infarcted area in untreated animals was 
lost as a result of intramyocardial injection of GFs.  
It could be argued that a single injection of cells or GFs hardly promotes a 
sustained and prolonged cardiac repair in the absence of a robust activation of 
autocrine/paracrine processes. Moreover, the question remains as to whether a 20% 
recovery of myocardial mass within the infarct, mostly consisting of small contractile 
cells, is sufficient to prevent the evolution of myocardial infarction toward cardiac 
decompensation. However, infarct size is proportional to the number of lost 
cardiomyocytes, representing the major determinant of unfavorable LV remodeling and 
its chronic evolution toward heart failure (Olivetti G et al. 1991). Hence it is of 
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relevance that the GF-mediated generation of young functionally competent 
cardiomyocytes succeeds in making cardiac function and anatomy independent of the 
amount of tissue lost by the occlusion of the supplying coronary artery. These results 
suggest that locally delivered GFs, by reversing the hostile microenvironment of 
scarred myocardium, promote a cardiac repair which is proportional to tissue demand.  
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B) STUDY ON ACUTE MYOCARDIAL INFARCTION 
- High-mobility group box 1 protein (HMGB1)  
HMGB1 is a multifunctional protein which has both nuclear and extracellular 
functions. The protein was originally identified as a nonhistone DNA-binding nuclear 
protein: it binds DNA in a sequence independent manner and modifies DNA structure to 
facilitate transcription, replication, and repair (Bustin M 1999). More recently, a novel 
role for HMGB1 as a cytokine was identified. Indeed HMGB1 is a potent mediator of 
inflammation, it is secreted by activated macrophages in response to pro-inflammatory 
cytokines (Limana F et al. 2005) and released passively from necrotic cells. 
Furthermore, several lines of evidence demonstrated that the effects of the extracellular 
HMGB1 are mediated, at least in part, by its binding to the receptor for advanced 
glycation end products (RAGE), a multiligand receptor of the immunoglobulin super-
family. It has been reported that HMGB1 is a strong chemo-attractant and a pro-
proliferative molecule for vessel-associated stem cells (mesoangioblasts).  HMGB1 was 
shown to act as a signal of tissue damage and to promote proliferation, migration, and 
differentiation of several stem cell types (Degryse B et al. 2001; Palumbo R et al. 
2004). Finally, experimental evidence has been provided that intramyocardial 
administration of exogenous HMGB1 induces resident cardiac progenitor cell 
proliferation and differentiation, in the murine infarcted heart (Limana F et al. 2005). 
This effect,  mediated at least in part by paracrine mechanisms (Rossini A et al. 2008), 
promotes myocardial regeneration, induces a recovery of LV mechanical function, and 
partially prevents LV remodeling after coronary artery occlusion.  
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- Recovery of electrical function  
HMGB1 has been reported to have both beneficial and detrimental effects (Lotze 
MT et al. 2005) , and these opposite actions were observed in response to “low” and 
“high” HMGB1 levels, respectively. In the present study, HMGB1 was administered 
locally at very low dose (2 µg) which is approximately 1000-fold less than that required 
to induced septic-shock. In addition,  HMGB1 was  injected into the heart in a critical 
time window, before necrosis and the associated endogenous HMGB1 increase 
occurred.  
The results reported here demonstrate that the delivery of HMGB1 into the rat 
heart at the time of acute ischemia induces a recovery of electrical function as suggested 
by the decline in the occurrence of stress-induced ventricular arrhythmias.  Although 
further studies are required to better understanding the mechanisms underlying the anti-
arrhythmic action of the treatment, in accordance with previous studies (Limana F et al. 
2005; Rossini A et al. 2008), this result can be at least in part ascribed to the HMGB1-
induced cardiac regeneration resulting from CPC activation associated with a proper 
electro-mechanical integration of the newly formed tissue with the spared ventricular 
myocardium.  
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